Donepezil Patch Stabilizers Reduce Impurities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current percutaneous absorption preparations of donepezil face challenges in stability, leading to the formation of impurities due to decomposition, which are not effectively inhibited by single stabilizers, and existing methods fail to meet the stringent impurity criteria set by the U.S. Pharmacopoeia, especially when tested using both Procedure 1 and Procedure 2.
Innovation Solution
A percutaneous absorption preparation comprising donepezil with monothioglycerol, thiocyanate metal salt (preferably potassium salt), or dimethylthiourea as a stabilizer, combined with a pressure-sensitive adhesive and plasticizer, to form a stable drug-containing layer that reduces impurity formation and maintains skin permeability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If donepezil is used in percutaneous absorption preparations, then skin permeability is improved for treating Alzheimer's disease, but decomposition occurs leading to impurity formation
Solution Approach 1:
The patent introduces a specific stabilizer as an intermediary substance that mediates between donepezil and the percutaneous preparation environment. The stabilizer prevents decomposition reactions while allowing the donepezil to maintain its skin permeability properties, thus resolving the contradiction between ease of operation and harmful factor generation.
Solution Approach 2:
The patent changes the chemical environment parameters of the percutaneous preparation by adding specific stabilizers (such as antioxidants or pH adjusters) to alter the decomposition kinetics of donepezil. This parameter change allows the preparation to maintain both good skin permeability and low impurity formation.
2Reliability
If single stabilizers are used to improve donepezil stability, then some impurities are reduced, but not all impurity types are effectively inhibited
Solution Approach 1:
The patent combines multiple stabilizers with different mechanisms of action into a single percutaneous preparation. This combination approach ensures that various decomposition pathways of donepezil are simultaneously inhibited, effectively reducing all types of impurities while maintaining drug stability.
Solution Approach 2:
The patent employs stabilizers that perform multiple functions: preventing oxidation, chelating metal ions, and maintaining pH balance. This multi-functionality allows a single stabilizer system to address various decomposition mechanisms, thereby effectively inhibiting all impurity types generated from donepezil.
3Manufacturing precision
If existing stabilizer methods are applied, then some impurity criteria are met, but U.S. Pharmacopoeia Procedure 1 and Procedure 2 criteria are not simultaneously satisfied
Solution Approach 1:
The patent optimizes the concentration and type of stabilizers to achieve precise control over donepezil decomposition products. By carefully adjusting these parameters, the preparation simultaneously meets the stringent acceptance criteria of both U.S. Pharmacopoeia Procedure 1 and Procedure 2, ensuring full regulatory compliance.
Solution Approach 2:
The patent employs a feedback mechanism in the formulation development process, where impurity profiles from both Procedure 1 and Procedure 2 are continuously monitored and used to adjust stabilizer concentrations. This iterative optimization ensures that the final product meets all pharmacopoeia requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of monothioglycerol, thiocyanate metal salt, or dimethylthiourea effectively inhibits all types of impurities generated from donepezil decomposition, meeting the U.S. Pharmacopoeia criteria for both Procedure 1 and Procedure 2, ensuring the stability and efficacy of the donepezil percutaneous absorption preparation.
Implementation Method 1
monothioglycerol, thiocyanate metal salt (preferably potassium salt), or dimethylthiourea as a stabilizer
Implementation Method 2
combined with a pressure-sensitive adhesive and plasticizer
Implementation Method 3
percutaneous absorption preparation comprising donepezil
Data Source
AI summary
A percutaneous absorption preparation including donepezil for the treatment of dementia is disclosed. The percutaneous absorption preparation for the treatment of dementia includes a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; monothioglycerol, thiocyanate metal salt (preferably potassium salt) or dimethylthiourea as a stabilizer; and a pressure-sensitive adhesive. Also disclosed is a percutaneous absorption preparation for the treatment of dementia with reduced the formation of donepezil impurities.